

Sustainable Pharmaceuticals Short Life Working Group

28th November 2019

NHS England and NHS Improvement






- 17th October 2019 Roundtable Discussion
- 23rd October 2019 Short Life Working Group established
- NHS Long Term Plan commitments
 - Inhaled Anaesthetics
 - Inhalers
- Next Steps to be decided



HSC Carbon Footprint 2017¹

Figure 4. Health and Social care detailed breakdown 2017





1 SDU, PHE & NHSE Reducing the use of natural resources in health and social care 2018 report



Inhaled Anesthetics Metric

- Model Hospital Metric for Trusts to benchmark Sevoflurane use
- Secondary care data (Define RxInfo®) fed into the metric from Hospital Pharmacy and Medicines Optimisation Team









We are delighted to formally launch Severn Environmental Anaesthesia and Sustainability Network, we are in a climate emergency and through collaborative working in healthcare we will have a positive impact. Please join us or get in touch! #sustainable #anaesthesia #healthcare




3:47 am - 21 Nov 2019



Clare Topping PhD @enviromentalist · Nov 19

Really pleased that nearly all @NGHnhstrust anaesthetists that answered our survey were aware of the Enviro impact of inhaled agents and most support a target to reduce ghg emissions from anaesthetic gases





Life Didn't Begin At 40 @did 40 - Nov 21









Asthma inhalers as bad for the environment as eating meat Switching 10% of inhalers to ones that do not use liquefied compressed gas could reduce CO2 emissions by 58,000 tonnes a year.

Patient decision aid

Inhalers for asthma

Information to help people with asthma and their hamiltone preferacionals discours their options for inhaler and their hamiltone preferacionals discours their options for inhaler devices.

It is suitable for use by people aged 17 years and over.

About this patient decision aid

Authors affects the arrange and can make it difficult to breath. It may cause symptoms such as chest tightness, wheecaness or coupling, the patient devices that deliver a medicane is that has been as the set to be a second or the second of the second of

Inhalers:
transitioning
from shared
priorities to a
shared
approach

BMJ Open. 2019 Oct 29;9(10):e028763. doi: 10.1136/bmjopen-2018-028763.

8:16 am - 21 Nov 2019

Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England.

Wilkinson AJK1, Braggins R2, Steinbach I3, Smith J2.


Author information


- 1 Respiratory Department, East and North Hertfordshire NHS Trust, Stevenage, UK alex wilkinson2@nhs.net.
- 2 Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- 3 Centre for Sustainable Healthcare, Oxford, UK.







ePACT 2 Dashboard












Open Prescribing

Environmental Impact of Inhalers





The NHS Long Term Plan 67

Clinical
Pharmacy and
Environmentally
Sustainable
Medicines Use

3.86. We will do more to support those with respiratory disease to receive and use the right medication. 90% of NHS spend on asthma goes on medicines¹³⁶, but incorrect use of medication can also contribute to poorer health outcomes and increased risk of exacerbations, or even admission. Pharmacists in primary care networks will undertake a range of medicine reviews, including educating patients on the correct use of inhalers and contributing to multidisciplinary working. As part of this work, they can also support patients to reduce the use of short acting bronchodilator inhalers and switch to dry powder inhalers where clinically appropriate, which use significantly less fluorinated gases than traditional metered dose inhalers¹³⁷. Pharmacists can also support uptake of new smart inhalers, as clinically indicated.



Next Steps to be decided

- Short Life Working Group (SLWG) on sustainable medicines use will continue to collaborate with existing workstreams
- SLWG will continue to report to the NHSE/I Sustainability Board
- Scoping opportunities across the pharmaceutical supply chain, prescribing and dispensing
 - Opportunities
 - Challenges
- Engaging with key stakeholders in clinical practice, professional bodies, pharmaceutical industry and medicines regulation